

**Jubilant Pharma Australia Pty Ltd**  
**Balance Sheet as at 31 March 2024**  
(All amounts in AUD, unless otherwise stated)

	Notes	As at 31 March 2024	As at 31 March 2023
<b>ASSETS</b>			
<b>Current assets</b>			
Financial assets			
i.	3	17,664	20,486
ii.	4	14,684	18,880
<b>Total current assets</b>		<b>32,348</b>	<b>39,366</b>
<b>Total assets</b>		<b>32,348</b>	<b>39,366</b>
<b>EQUITY AND LIABILITIES</b>			
<b>Equity</b>			
Equity share capital	5	20,000	20,000
Other equity		(41,037)	(42,774)
<b>Total equity</b>		<b>(21,037)</b>	<b>(22,774)</b>
<b>Liabilities</b>			
<b>Current liabilities</b>			
Financial liabilities			
i.	6	53,385	62,140
<b>Total current liabilities</b>		<b>53,385</b>	<b>62,140</b>
<b>Total liabilities</b>		<b>53,385</b>	<b>62,140</b>
<b>Total equity and liabilities</b>		<b>32,348</b>	<b>39,366</b>

**For Jubilant Pharma Australia Pty Ltd.**

Dr. Jaidev Sanjeev Rajpal  
Director

Date: May 27, 2024

**Jubilant Pharma Australia Pty Ltd**  
**Statement of Profit and Loss for the year ended 31 March 2024**  
**(All amounts in AUD, unless otherwise stated)**

	Notes	For the year ended 31 March 2024	For the year ended 31 March 2023
Revenue from operations	7	29,713	44,710
<b>Total income</b>		<b>29,713</b>	<b>44,710</b>
<b>Expenses</b>			
Other expenses	8	27,976	42,529
<b>Total expenses</b>		<b>27,976</b>	<b>42,529</b>
<b>Profit before exceptional items and tax</b>		<b>1,737</b>	<b>2,181</b>
Exceptional items		-	-
<b>Profit before tax</b>		<b>1,737</b>	<b>2,181</b>
<b>Total tax expense</b>		<b>-</b>	<b>-</b>
<b>Profit for the year</b>		<b>1,737</b>	<b>2,181</b>
<b>Other comprehensive loss for the year, net of tax</b>		<b>-</b>	<b>-</b>
<b>Total comprehensive income for the year</b>		<b>1,737</b>	<b>2,181</b>

**Jubilant Pharma Australia Pty Ltd**  
**Statement of Cash Flows for the year ended 31 March 2024**  
**(All amounts in AUD, unless otherwise stated)**

	<b>As at</b>	<b>As at</b>
	<b>31 March 2024</b>	<b>31 March 2023</b>
<b>A. Cash flow from operating activities</b>		
Net profit before tax	1,737	2,181
<b>Operating cash flow before working capital changes</b>	<b>1,737</b>	<b>2,181</b>
Decrease in trade receivables, loans, other financial assets and other assets	2,822	444
(Decrease)/ Increase in trade payables, other financial liabilities, other liabilities and provisions	(8,755)	5,280
<b>Cash (used in)/ generated from operations</b>	<b>(4,196)</b>	<b>7,905</b>
Income tax paid (net of refund)	-	-
<b>Net cash (used in)/ generated from operating activities</b>	<b>(4,196)</b>	<b>7,905</b>
<b>B. Cash flow from investing activities</b>		
Net cash generated from investing activities	-	-
<b>C. Cash flow from financing activities</b>		
Net cash generated from financing activities	-	-
<b>Net (decrease)/ increase in cash and cash equivalents (A+B+C)</b>	<b>(4,196)</b>	<b>7,905</b>
Cash and cash equivalents at the beginning of year	18,880	10,975
<b>Cash and cash equivalents at the end of the year</b>	<b>14,684</b>	<b>18,880</b>

**Jubilant Pharma Australia Pty Ltd**  
**Statement of Changes in Equity for the year ended 31 March 2024**  
**(All amounts in AUD, unless otherwise stated)**

<b>A. Equity share capital</b>	<b>Amount</b>
<b>Balance as at 1 April 2022</b>	<b>20,000</b>
Changes in equity share capital during the year	-
<b>Balance as at 31 March 2023</b>	<b>20,000</b>
Changes in equity share capital during the year	-
<b>Balance as at 31 March 2024</b>	<b>20,000</b>

**B. Other equity**

	<u>Reserves and surplus</u>	<u>Total</u>
	Retained earnings	
<b>Balance as at 1 April 2022</b>	<b>(44,955)</b>	<b>(44,955)</b>
Profit for the year	2,181	2,181
<b>Total comprehensive income for the year</b>	<b>2,181</b>	<b>2,181</b>
<b>Balance as at 31 March 2023</b>	<b>(42,774)</b>	<b>(42,774)</b>
Profit for the year	1,737	1,737
<b>Total comprehensive income for the year</b>	<b>1,737</b>	<b>1,737</b>
<b>Balance as at 31 March 2024</b>	<b>(41,037)</b>	<b>(41,037)</b>

**Jubilant Pharma Australia Pty Ltd**  
**Notes to the financial statements for the year ended 31 March 2024**

---

**Note 1: Corporate information**

Jubilant Pharma Australia Pty Ltd (“the Company”) is a for-profit proprietary Company, incorporated and domiciled in Australia. The Company is a wholly owned subsidiary of Jubilant Pharma Limited (“the holding company”) whose ultimate parent company is Jubilant Pharmova Limited, a company incorporated in India.

The principal activity of Jubilant Pharma Australia Pty Ltd is applying, obtaining and maintaining market authorisation in its name and acting as the importer and distributor of pharmaceuticals products.

**Note 2. Material accounting policies**

This note provides a list of the significant accounting policies adopted in the preparation of these financial statements. The accounting policies adopted are consistent with those of the previous financial year.

**(a) Basis of preparation**

**(i) Statement of compliance**

These financial statements with limited information have been prepared solely for consideration in the consolidated financial statements of the Ultimate Parent Company. These financial statements have been prepared in accordance with the Ultimate Parent's accounting policies which are in agreement with the recognition and measurement principles laid down under the Companies (Indian Accounting Standards) Rules, 2015, as amended.

**(ii) Historical cost convention**

These financial statements have been prepared under historical cost convention on accrual basis, unless otherwise stated.

**(b) Functional and presentation currency**

Items included in the financial statements of the Company are measured using the currency of the primary economic environment in which the entity operates (i.e. the "functional currency"). The functional currency of the Company is Australian Dollars (“AUD”). These financial statements are presented in AUD.

**(c) Current versus non-current classification**

The Company presents assets and liabilities in the Balance Sheet based on current/non-current classification.

An asset is treated as current when:

- It is expected to be realised or intended to be sold or consumed in normal operating cycle;
- It is held primarily for the purpose of trading;
- It is expected to be realised within twelve months after the reporting period; or
- It is cash or cash equivalent unless restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period.

The Company classifies all other assets as non-current.

A liability is current when:

- It is expected to be settled in normal operating cycle;
- It is held primarily for the purpose of trading;
- It is due to be settled within twelve months after the reporting period; or
- There is no unconditional right to defer the settlement of the liability for at least twelve months after the reporting period.

The Company classifies all other liabilities as non-current.

Deferred tax assets and liabilities are classified as non-current assets and liabilities respectively.

The operating cycle is the time between the acquisition of assets for processing and their realisation in cash and cash equivalents. The Company has identified twelve months as its operating cycle for the purpose of current-non-current classification of assets and liabilities.

**Jubilant Pharma Australia Pty Ltd**  
**Notes to the financial statements for the year ended 31 March 2024**  
**(All amounts in AUD, unless otherwise stated)**

---

**Note 3: Trade receivables**

	<u>As at</u>	<u>As at</u>
	<u>31 March 2024</u>	<u>31 March 2023</u>
<b>Unsecured and current</b>		
Trade receivables - considered good	17,664	20,486
<b>Total trade receivables</b>	<u><u>17,664</u></u>	<u><u>20,486</u></u>

---

**Note 4: Cash and cash equivalents**

	<u>As at</u>	<u>As at</u>
	<u>31 March 2024</u>	<u>31 March 2023</u>
<b>Balances with banks</b>		
- in current accounts	14,684	18,880
<b>Total cash and cash equivalents</b>	<u><u>14,684</u></u>	<u><u>18,880</u></u>

**Jubilant Pharma Australia Pty Ltd**  
**Notes to the financial statements for the year ended 31 March 2024**  
**(All amounts in AUD, unless otherwise stated)**

**Note 5: Equity share capital**

	As at	As at
	31 March 2024	31 March 2023
<b>Paid up share capital</b>		
20000 Common stock of no par value	20,000	20,000
	<b>20,000</b>	<b>20,000</b>

<b>Movement in equity share capital</b>	<b>No. of shares</b>	<b>Amount</b>
As at 1 April 2022	20,000	20,000
Additions during the year	-	-
As at 31 March 2023	20,000	20,000
Additions during the year	-	-
As at 31 March 2024	20,000	20,000

**Terms and rights attached to equity shares**

The Company has only one class of Common stock referred to herein as equity shares. Each holder of common stock is entitled to one vote per common stock. In the event of liquidation of the Company, the stockholders shall be entitled to receive all of the remaining assets of the Company, after distribution of all preferential amounts, if any. Such amounts will be in proportion to the number of common stock of equity shares held by the stockholders.

**Details of shareholders holding more than 5% shares in the Company:**

	As at		As at	
	31 March 2024		31 March 2023	
	No. of shares	% holding	No. of shares	% holding
<b>Jubilant Pharma Limited - the holding company</b>	20,000	100.00%	20,000	100.00%
Common stock of no par value				

**Jubilant Pharma Australia Pty Ltd**  
**Notes to the financial statements for the year ended 31 March 2024**  
**(All amounts in AUD, unless otherwise stated)**

---

**Note 6: Trade payables**

	<u>As at</u>	<u>As at</u>
	<u>31 March 2024</u>	<u>31 March 2023</u>
<b>Current</b>		
Dues to relates parties	38,035	43,000
Dues to others	15,350	19,140
<b>Total trade payables</b>	<u><u>53,385</u></u>	<u><u>62,140</u></u>



**Jubilant Pharma Australia Pty Ltd**  
**Notes to the financial statements for the year ended 31 March 2024**  
**(All amounts in AUD, unless otherwise stated)**

**Note 7: Revenue from operations**

	<b>For the year ended</b>	<b>For the year ended</b>
	<b>31 March 2024</b>	<b>31 March 2023</b>
Sale of products		
Sale of services	29,713	44,710
<b>Total revenue from operations</b>	<b>29,713</b>	<b>44,710</b>

**Note 8: Other expenses**

	<b>For the year ended</b>	<b>For the year ended</b>
	<b>31 March 2024</b>	<b>31 March 2023</b>
Rates and taxes	403	748
Payments to statutory auditors	6,710	7,040
Legal and professional fees	19,585	32,032
Bank charges	1,278	2,709
<b>Total other expenses</b>	<b>27,976</b>	<b>42,529</b>